An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC
A phase 2 trial of FAP-2286, Lutetium-177 vipivotide tetraxetan in prostate cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.
Overview
An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC is a phase 2 interventional study registered as NCT06894511 by Novartis Pharmaceuticals, with 7 participants enrolled, started 2025-09-11 and due to reach its primary completion in 2026-10-15. Interventions recorded: AAA617, ARPI: Abiraterone, ARPI: Enzalutamide. Conditions listed: Metastatic Castration Resistant Prostate Cancer (mCRPC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Shares Novartis, Metastatic castration-resistant prostate cancer, Lutetium-177 vipivotide tetraxetan, Prostate cancer.
- TrialONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
Shares Metastatic castration-resistant prostate cancer, Lutetium-177 vipivotide tetraxetan, Prostate cancer, Lutetium-177.
- TrialAnti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Shares FAP-2286 (177Lu / 68Ga), Metastatic castration-resistant prostate cancer, Prostate cancer, Lutetium-177.
- TrialAn Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Shares FAP-2286 (177Lu / 68Ga), Novartis, Prostate cancer, Lutetium-177.
- TrialOpen-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Shares Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer, Lutetium-177.
- TrialA Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA
Shares Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer, Lutetium-177.
- TrialA Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
Shares Metastatic castration-resistant prostate cancer, Prostate cancer, Lutetium-177.
- TrialStudy Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Shares Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer.